Deal covers Dlyoject for the potential treatment of moderate-to-severe pain.
Baxter Healthcare inked a commercial supply agreement with Javelin Pharmaceuticals to provide additional manufacturing capacity for Javelin’s injectable diclofenac, Dyloject™.
Dylojectinjectable diclofenac sodium is under review for marketing approval in the U.K. for the treatment of acute moderate-to-severe pain. In the U.S., Dyloject is in Phase III trials for the same indication.
Baxter will serve as a secondary manufacturer of Dyloject pending regulatory approval. The deal, which supplements an existing collaboration, has a three-year, renewable term and sets forth minimum purchase and production requirements.
